The name most often mentioned as a potential acquirer is Merck (MRK). Merck management has said during conference calls that it would augment its pipeline with external opportunities.
$MNKD what big pharma wouldn't want the next insulin therapy. They could make Billions.? Mark Roman (@markromantrader) Jun. 4 at 11:02 AM
$MNKD No one will bid higher than Merck since they have no insulin which will be cannibalized by AFREZZA!!? Joe (@joebyu12) Jun. 4 at 10:38 AM
$MNKD Mann planned for along time, big pharmas love mann, would not be surprised if arrangement already made for partner or buyout.? Mark Turner (@going1green) Jun. 4 at 10:36 AM
At the time of publication, the author held no positions in any of the stocks mentioned.
This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.